All News

Checklist IgG4

Prevalence and Mortality of IgG4-related disease in the USA

Jack Cush, MD

A current review of the epidemiology of IgG4-related disease (IgG4-RD) in the USA shows a low prevalence with possibly increasing numbers, owing to increasing awareness of this unique immune-mediated condition.

Read Article
brain headache neuro

Treatment and Management of Neuropsychiatric Lupus

Eric Dein, MD

On the first day of ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus. Dr. Petri, a lupus expert from Johns Hopkins Rheumatology, reviewed the latest clinical and animal model studies that offer hope in treatment and gave wide-ranging pearls on a variety of issues that can be faced in this disorder. 

Read Article
GCA temporal artery

Aging Mechanisms Tied to Giant Cell Arteritis

MedPage Today

Senescence pathways are involved in giant cell arteritis (GCA), an analysis of patient tissue samples suggested, which may account for the efficacy of one agent now used for the disease and another in commercial development.

Read Article
RheumNow Podcast square

The Match Game (4.14.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, including Rheumatology success in the NRMP MATCH, Cocaine vasculitis and worrisome safety risks with Biologics and tsDMARDs.

Read Article
epilepsy,brain,seizure,CVA

Antiphospholipid Antibodies With Incident Cardiovascular Events

Jack Cush, MD

Are antiphospholipid antibodies (aPL) associated with atherosclerotic cardiovascular (ASCVD) event risk?  A cohort study has shown that aPL Abs are found in a substantial proportion of adults with ASCVD events and finding both positive aCL IgA and aβ2GPI IgA Abs independently predicted futur

Read Article
hospital-834152_640.jpg

Steroid-Sparing Rituximab in Polymyalgia Rheumatica

Jack Cush, MD

BRIDGE-PMR proof-of-concept trial assessed the efficacy of rituximab (RTX) in patients with polymyalgia rheumatica (PMR) and showed that a single 1000 mg dose of lead to a significant number of glucocorticoid-free remissions after 1 year. 

Read Article
Tuesday Night Rheumatology: POD 3: Vasculitis: Evolution and Advances This webinar will feature highlights from these lectures followed by live audience Q & A: -New Therapies for PMR & GCA -Assessment of GCA and PMR -GPA Treatment Choices https://t.co/PRj6QQnxIS https://t.co/Y4aCyTrg0Z

Links:

Dr. John Cush RheumNow ( View Tweet)
Tuesday Night Rheumatology: POD 3: Vasculitis: Evolution and Advances This webinar will feature highlights from these lectures followed by live audience Q & A: -New Therapies for PMR & GCA -Assessment of GCA and PMR -GPA Treatment Choices https://t.co/MQBAEmUvuC https://t.co/qh2By6a3Kf

Links:

Dr. John Cush RheumNow ( View Tweet)
PJP Prophylaxis Needed with Steroids and RTX The 2023 EULAR Vasculitis guidelines recommends primary prophylaxis with antibiotics, especially in rheumatic disease patients receiving RTX. https://t.co/eq42bK7MB1 https://t.co/Wk1hOpXanv

Links:

Dr. John Cush RheumNow ( View Tweet)
Aging Mechanisms Tied to Giant Cell Arteritis Senescence pathways are involved in GCA, an analysis of patient tissue samples suggested, which may account for the efficacy of one agent now used for the disease and another in commercial development. https://t.co/nPSidkCvDk https://t.co/FNbbSPpZVS

Links:

Dr. John Cush RheumNow ( View Tweet)
Aging Mechanisms Tied to Giant Cell Arteritis Senescence pathways are involved in GCA, an analysis of patient tissue samples suggested, which may account for the efficacy of one agent now used for the disease and another in commercial development. https://t.co/H2nzmQkSst https://t.co/JE7h9ihJUx

Links:

Dr. John Cush RheumNow ( View Tweet)
Real world interchangeabilty study compared rituximab to biosimilar ( CT-P10) in 128 Rheum pts (CT-P10= 64; RTX= 64), with 41% of pts switched from RTX to CT-P10. Both Rx had Comparable Gr 2 infuxion Rxs, infection #s & hypogammaglobulinemia (p > 0.05) https://t.co/RNxt7Xn7MJ https://t.co/u3yJNQQIMC

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 42 pts w/ cocaine-induced midline or systemic vasculitis; Current cocaine use common (20/23 + urine tox, including pts who prev. deniedcocaine). Found: septal perfs (75%), oronasal fistula(15%), less(27%) systemic Sxs, 56% PR3-ANCA+https://t.co/tCt8l6Neb3 https://t.co/LzEpP5Z2fT

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 42 pts w/ cocaine-induced midline or systemic vasculitis; Current cocaine use common (20/23 + urine tox, including pts who prev. deniedcocaine). Found: septal perfs (75%), oronasal fistula(15%), less(27%) systemic Sxs, 56% PR3-ANCA+https://t.co/z1Z4INRSj5 https://t.co/v9ZyZD1Lrb

Links:

Dr. John Cush RheumNow ( View Tweet)
Steroid-Sparing Rituximab in Polymyalgia Rheumatica https://t.co/FDvVSFnuDf https://t.co/s6B2AZrv1T

Links:

Dr. John Cush RheumNow ( View Tweet)
Updated AAV Treatment Recommendations AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include GPA, microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). https://t.co/gQr92GpE5j https://t.co/SGDh1uNg2b

Links:

Dr. John Cush RheumNow ( View Tweet)
Updated AAV Treatment Recommendations AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include GPA, microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). https://t.co/YCNGYZfSr1 https://t.co/MFs9ykm4fb

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2023 Year in Review New Drugs in Old Disease? GCA - Tocilizumab (GiACTA ), Secikinumab (TitAIN), Mavrilimumab (GM-CSFr mAb) PMR - Sarilumab (SAPHYR), TCZ (PMR-Spare, SEMAPHORE), Tofacitinib (EAST PMR) @RheumNow https://t.co/cY2HuaI6uM
Eric Dein ericdeinmd ( View Tweet)
An exciting year and time for GCA and PMR treatment! - Tocilizumab (IL-6i) - Secukinumab (IL-17i) - Sarilumab (IL-6i) - Mavrilimumab (GM-CSF receptor mAb) - Tofacitinib (JAKinib) @RheumNow #RNL2023 https://t.co/d0T2RAssFY
Robert B Chao, MD doctorRBC ( View Tweet)
Extension PEXIVAS study in ANCA vasculitis pts with severe DAH - no significant effect of PLEX on mortality but do note numerical difference, favoring PLEX in severe DAH - note difference in curve @RheumNow #RNL2023 https://t.co/6ktb3Uakw9
Robert B Chao, MD doctorRBC ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×